66 results about "Behavioural disorders" patented technology

The present invention is directed to a method for the treatment of a patient suffering from psychiatric and behavioral disorders, including post partum depression, post traumatic stress disorder, compulsive smoking, attention deficit hyperactivity disorder, gambling addiction, comprising the step of administering a stellate ganglion block to the patient to alleviate the symptoms. The stellate ganglion block may be followed by a sympathectomy to provide permanent relief.

The invention provides a compound for use in the treatment of symptoms associated with psychosis, schizophrenia, a cognitive impairment disorder, a mood disorder, a nervous system disorder and/or a behavioral disorder. The compound has the formula ? and is administered to a subject in need thereof in an effective amount. The compound Meparfynol (3-methylpent-1-yn-3-ol) has been found to be effective.

The invention discloses a rapid eye movement period sleep behavior disorder classification method based on sleep electroencephalogram. The method comprises the following steps: preprocessing an acquired sleep electroencephalogram signal of a patient, acquiring an electroencephalogram signal of an electroencephalogram interval in a sleep R period, cutting according to a preset signal length to acquire a plurality of sub-signal segments, layering an original electroencephalogram signal of each sub-signal segment, and enabling a frequency domain component after wavelet transform to approximatelycorrespond to different wave bands of original electroencephalogram according to the frequency of the electroencephalogram; carrying out empirical mode decomposition (EMD) to obtain a multilayer intrinsic mode function (IMF); performing feature extraction on the electroencephalogram signals of different wave bands and the multilayer intrinsic mode function, and performing dimensionality reductionon the feature set PCA to obtain a low-dimensional feature set; and carrying out classification and identification by using the feature set after dimension reduction, and classifying patients suffering from Parkinson's disease accompanied by rapid eye movement sleep disorder, Parkinson's disease not accompanied by rapid eye movement sleep disorder and idiopathic rapid eye movement period sleep behavior disorder. Complex PSG detection is simplified into electroencephalogram detection, a whole night does not need to be consumed, the number of times of measurement is reduced, an accurate recognition result is obtained, and then a very good auxiliary effect can be achieved on treatment of the illness state of a patient.

The present invention is one kind of red peony injection prepared with red peony root as material and through alcohol extraction, n-butanol extraction or macroporous resin purification, and adding proper amount of medicinal supplementary material and injection water. It is stable and may be used in intramuscular injection, intravenous injection and intravenous instillation. Pharmacodynamic experiment shows that the medicine of the present invention can improve the behavior disorder of rat with cerebral infarction obviously, reduce the area of cerebral infarction, decrease water content in infracted brain tissue, reduce the peroxidation damage of lipoid in brain tissue and raise the acute oxygen lack tolerance of mouse and thus has excellent treat effect on cerebral infarction.

Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, ALS, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for evaluation in animal models of neurodegenerative diseases.

A system and method are provided for treating excessive or problematic computer use. In at least one embodiment, a method is employed to treat excessive or problematic computer use by acquiring information about the unwanted user activity, monitoring user activity for the unwanted behavior, controlling the behavior when it occurs, enabling the user to record self-observations and evaluating the results. This method may employ a computer based system to treat excessive or problematic computer use which includes configuring a user activity monitor with constraints, programmatically enforcing those constraints, reporting the activities monitored and restricted, and enabling a user to input self-observations. Potential constraints include a complete bar on the user activity, as well as, progressively decreasing the amount of time the user may engage in the activity, i.e. titrating the user activity.

The invention belongs to the technical field of medicine and discloses a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases. The pharmaceutical composition is prepared by ginsenoside and carithamine as main ingredients and can be prepared into pharmaceutically or clinically acceptable dosage forms. The pharmaceutical composition has functions of expanding blood vessels of brain, reducing cerebral vascular resistance, increasing cerebral blood flow, obviously minimizing infarct area of brain tissues, obviously lightening behavior disorders caused by brain tissue necrosis, and the like, and can be used for preparing medicaments for treating diseases such as cerebral circulation insufficiency, cerebral thrombosis, cerebral embolism, brain blood vessels spasm, brain insufficiency, senile dementia, Parkinsonism, cerebral apoplexy, hypertension, hyperlipemia, arteriosclerosis, coronary heart disease, angina pectoris, miocardial infarction, etc.

The present invention is directed to aryl sulfamide derivatives of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and donepezil or rivastigmine or galantamine or a pharmaceutically acceptable salt of thereof is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.

The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.

The invention discloses a probiotic composition for treating rapid eye movement sleep behavior disorder (RBD) in patients with Parkinson disease (PD). The composition is prepared from bacillus licheniformis, bifidobacterium longum, lactobacillus acidophilus, enterococcus faecalis and pharmaceutically acceptable auxiliary materials, wherein the number of live bacteria of the bacillus licheniformisis not less than 10.0x10<8> CFU/g; the number of live bacteria of the bifidobacterium longum is not less than 4.0x10<8> CFU/g; the number of live bacteria of the lactobacillus acidophilus is not lessthan 1.0x10<8> CFU/g; and the number of live bacteria of the enterococcus faecalis is not less than 0.5x10<8> CFU/g. In the probiotic composition, the components have a synergistic effect, the RBD symptom in the PD patients can be effectively treated and improved, and the treatment effect is good in continuity and excellent in stability; the composition can effectively improve the motor symptom ofthe PD patients while having a treatment effect on the RBD symptom of the PD patients, and solves the problem that current drugs cannot treat the motor symptom and non-motor symptoms of the PD patients at the same time; and the composition can effectively reduce the dosage of levodopa in the PD patients and prevent the patients from generating resistance to levodopa prematurely, and has a betterprotection effect on the patients.

The invention presented personalized biofeedback computerized system, an End-to-End eHealth smart platform for analysis, diagnosis and therapy of types of behavioral disorders. The system comprises a Captive Portal (CP) data input for initial input data and for continuous input data, a database comprising data, a Computer Processing Manager (CPM) for processing the patient data and the database, a Graphical User Interface (GUI) for interfacing with a user, and an Electroencephalography (EEG) or hemoencephalography (HEG) cap for stimulating predetermined areas in the brain, wherein the CPM is interconnected to the CPP, the database and the GUI, the CPM provides instructions for cranial electrode mediated stimulation to the areas in the brain according to a predetermined patient data dependent protocol, and the database provides external data. A preferred embodiment of the invention is a multilayered bio-feedbacking system.

The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like.

A modulator of PDE1A and/or PDE1C can be used as a medicament, in particular in the prevention or treatment of synucleinopathies, such as multiple system atrophy, dementia with Lewy bodies, Parkinson's disease, pure autonomic failure, rapid eye movement sleep behavior disorder, inherited synucleinopathies caused by mutations or multiplications of the SNCA gene, or synucleinopathies caused by mutations in other genes including, but not limited to, GBA, LRRK2 and PARK2.

This invention relates to methods and compositions for diagnosing and treating neuropsychiatric disorders, such as schizophrenia, schizoaffective disorder, bipolar affective disorder, unipolar affective disorder and adolescent conduct disorder. In particular, the invention provides novel variants of CADPKL nucleic acid sequences, as well as novel CADPKL polypeptides encoded by these variant sequences. The variant CADPKL nucleic acid sequences provided by this invention, as well as the variant polypeptides they encode are ones that statistically correlate with the presence of a neuropsychiatric disorder in individuals. The invention therefore also provides methods and compositions for using these variant nucleic acids and polypeptides to diagnose and treat such neuropsychiatric disorders.

The invention discloses application of higenamine in prevention and treatment of Alzheimer's disease, and relates to the field of small molecule drugs in clinical medicine. The invention relates to the application of higenamine obtained through preclinical study of natural small molecule compounds inhibiting beta-amyloid polypeptide mediated [alpha]1-adrenergic receptor chronic activation cerebrovascular function change, Alzheimer's disease sample pathology change and preclinical research of cognitive impairment in prevention and treatment of Alzheimer's disease; the application or combined application of higenamine in inhibition of beta-amyloid polypeptide mediated [alpha]1-adrenergic receptor chronic activation cerebrovascular smooth muscle cell molecular signal pathway and cerebrovascular tissue activity, and improvement of cerebrovascular function changes, and Alzheimer's disease-like molecule pathology damage and behavioral disorders in Alzheimer's disease model mice is proved from molecule, cell and animal levels .

The invention relates to a pharmaceutical composition for treating ischemic cerebral apoplexy and a preparation method and application thereof. The pharmaceutical composition for treating ischemic cerebral apoplexy is prepared from, by weight, 3-12 parts of NADPH and 0.5-8 parts of apocynin. NADPH and apocynin are applied jointly and act cooperatively in a specific proportion, and the pharmaceutical composition can reduce the cerebral infarction volume, significantly relieve the behavior disorder of cerebral ischemia mice, relieve encephaledema, improve the long-term survival capability of mice and enhance neurological function recovery; besides, the treatment effect of the pharmaceutical composition on ischemic cerebral apoplexy is much better than that of NADPH and apocynin which are applied independently on ischemic cerebral apoplexy, and a synergistic effect is achieved when NADPH and apocynin are applied jointly. Thus, the pharmaceutical composition has the effect of treating ischemic cerebral apoplexy and can serve as a potential drug for treating ischemic cerebral apoplexy.